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Background: Surgical aortic valve replacement (SAVR) has been for many years the only effective treatment for patients with severe aortic 
stenosis. Transcatheter aortic valve implantation (TAVI) has recently emerged as an alternative treatment for in-operable and high risk surgical 
patients. Our objective was to examine the immediate post-procedural and midterm hemodynamic profile of the trans-femorally implanted 
CoreValve™ as compared to surgical bioprosthetic valve as shown by serial echocardiograms.
Methods:  Forty four patients who had undergone trans-femoral TAVI (CoreValve™ bioprostethic valve) were matched to 66 patients who had 
undergone SAVR using a bioprosthesis. Matching was done according to body surface area, left ventricular ejection fraction, left ventricular outflow 
tract dimensions, aortic valve gradients and measured effective orifice area (EOA). Doppler echocardiographic data was compared before the 
procedure, at discharge, and at 6-12 months follow up. All measurements were performed according to the ASE guidelines.
Results:  SAVR prosthetic size ranged from 21 to 27 mm. In the TAVI group 17 patients received a 26 mm prosthesis and 27 patients received 
a 29 mm prosthesis. TAVI patients were older, with more patients having renal failure and ischemic heart disease. At discharge, TAVI patients had 
lower peak and mean transprosthetic gradients compared to SAVR patients (17.1 vs. 26.3 mmHg, p<0.0001 and 9.3 vs. 15.1 mmHg, p<0.0001, 
respectively). EOA was bigger in the TAVI group (1.95 vs. 1.48 cm2, p<0.0001). Severe patient prosthetic mismatch (PPM); defined as an indexed 
aortic valve area≤0.65cm2/m2 was found in the 17 of the surgical patients (26%) and in none of the TAVI patients (p<0.0001). Mild to moderate 
aortic regurgitation was evident in 36% of the TAVI group compared to 8% in the SAVR group (p<0.001). These findings did not change at 6-12 
months follow-up (EOA was 1.90 vs. 1.54 cm2, p=0.004).
Conclusions:  The post-procedure and mid-term hemodynamic profile of TAVI seems to be better than that of SAVR as expressed by lower 
transprosthetic gradients, bigger effective orifice areas, and a lower prevalence of severe PPM, despite a higher prevalence of aortic regurgitation.
